Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases

INCLUSION CRITERIAL: * Age \> or = 18 years. * Karnofsky performance score \> or = 60. * Histopathologic confirmation of the diagnosis of a solid tumor malignancy. The brain metastasis diagnosis per se does not have to be pathologically confirmed if the clinical and neuro radiographic picture is typical. * MRI (or CT if the patient cannot undergo MRI) evidence of evaluable disease in the brain. * Absolute neutrophil count \> or = 1,500/mm³. Platelet count \> or = 100,000/mm³. * Hemoglobin \> or = 10 g/dl. * BUN and serum creatinine both \< 1.5 times upper limit of normal. * Total and direct bilirubin both \< 1.5 times upper limit of normal. * SGOT and SGPT both \< or = 3 times upper limit of normal. * Alkaline phosphatase \< or = 2 times upper limit of normal. * At least two weeks must have elapsed from brain biopsy, craniotomy, or other surgery. * Life expectancy \> or = 8 weeks. * Patient or their legal guardian or legal next-of-kin must provide written informed consent prior to patient's registration on study. * At least four weeks must have elapsed from previous external beam radiation therapy, or eight weeks from stereotactic radiosurgery. * Patients treated with radiosurgery should have evidence of progression at a distant site in the brain, or confirmation of tumor progression by biopsy or PET scan. EXCLUSION CRITERIA: * Previous treatment with temozolomide, dacarbazine or vinorelbine. * Patients who have not recovered from all acute toxicities of prior therapies. * Patients with evidence of leptomeningeal metastases or primary dural metastases. * Patients who are poor medical risks because of nonmalignant systemic disease, as well as those with acute infection requiring treatment with intravenous antibiotics. * Patients whose psychiatric condition would, in the judgment of the principal investigator, make it unlikely that they could adhere to the requirements of the protocol.